Contact us
English
Menu
Contact us
Pipeline EN

FLD-103: A Non-Surgical Treatment for Basal Cell Carcinoma with the Potential to Change Lives

Basal cell carcinoma (BCC) is the most common type of skin cancer and the most frequent form of all cancers. In North America, 3.6 million cases are diagnosed each year. BCC results from the uncontrolled growth of skin cells,  primarily in areas of the body that have been exposed to the sun for extended periods. Patients affected by BCC commonly develop tumors on the face, neck, scalp and arms. 

The standard treatment for BCC is surgical removal or excision. While non-surgical treatments exist, they are not indicated for all types of BCC and often show limited efficacy. As a result, many patients must undergo surgery, facing significant preoperative anxiety, psychological distress, and lengthy recovery periods. Mohs surgery is a commonly used technique, that involves cutting away layers of skin until there is no evidence of cancer. This procedure results in wounds that can frequently take months or even years to heal and can leave permanent scars on visible areas of the body. Additionally, patients with BCC are at a higher risk of developing new or multiple lesions, requiring repeated surgeries. 
 
Feldan Therapeutics is developing FLD-103, an efficient, non-surgical approach to treat BCC. This first-in-class intralesional treatment selectively targets BCC cells by disrupting an intracellular component involved in the pathophysiology of the disease. By minimizing side effects, avoiding scarring and the need for postoperative recovery, FLD-103 has the potential to become a non-surgical first-line option and life-changing treatment for patients suffering from BCCs.

Learn more about FLD-103 trial
FLD-103

FLD-201: An Inhaled Therapy for Bronchiectasis Targeting Mucus Overproduction

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic lung disease that affects over 500,000 individuals in North America. Patients with NCFB typically experience persistent coughing, excessive mucus production, recurrent respiratory infections, and inflammation. Among these symptoms, more than 80% of patients identify excessive mucus and sputum production as the most burdensome aspect of their daily lives (Aliberti et al., 2016). The overproduction of pathological mucus contributes to frequent exacerbations, characterized by a sudden worsening of symptoms that require medical attention. Exacerbations are associated with accelerated lung function decline and disease progression.
 
Currently, there are no approved therapies for NCFB. To manage the accumulated mucus in their lungs, most patients rely on Airway Clearance Techniques (ACTs). However, these methods are often ineffective and time-consuming, which significantly impacts patients’ quality of life while still leaving them vulnerable to exacerbations.

Feldan Therapeutics is developing FLD-201, an inhaled antisense oligonucleotide (ASO) therapy designed to address the mucus burden in NCFB patients. By targeting key pathways involved in mucus hypersecretion, FLD-201 aims to clear the accumulated pathological mucus from patients’ airways, reduce the frequency of exacerbations, and drastically improve their quality of life.